Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia

by Neal Shore, Ronald Tutrone, Claus G. Roehrborn
Published 2019-01-01

343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agen...

by Ben Li, Neal Shore, Charles Schloss, Daniel Petrylak, Karim Fizazi, Mostefa Bennamoun, Raffaele Ratta, Josep Piulats
Published 2020-11-01

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

by Gary D Steinberg, Neal Shore, Petros Grivas, Matthew D Galsky, Elizabeth R Plimack, Shilpa Gupta, Arjun V Balar, Peter C Black, Matthew T Campbell, Gail S Dykstra, Christoper J Hoimes, Lidia P Lopez, Joshua J Meeks, Jonathan E Rosenberg, Ashish M Kamat
Published 2021-07-01

To defer or not to defer? A German longitudinal multicentric assessment of clinical practice in urology during the COVID-19 pandemic

by Nina N. Harke, Jan P. Radtke, Boris A. Hadaschik, Christian Bach, Frank P. Berger, Andreas Blana, Hendrik Borgmann, Florian A. Distler, Sebastian Edeling, Tobias Egner, Christina L. Engels, Mahmoud Farzat, Alexander Haese, Rainer Hein, Markus A. Kuczyk, Andreas Manseck, Rudolf Moritz, Michael Musch, Inga Peters, Sasa Pokupic, Bernardo Rocco, Andreas Schneider, André Schumann, Christian Schwentner, Chiara M. Sighinolfi, Stephan Buse, Jens-Uwe Stolzenburg, Michael C. Truß, Michael Waldner, Christian Wülfing, Volker Zimmermanns, Jörn H. Witt, Christian Wagner, Neal Shore
Published 2020-01-01